$2.91

0.26 (9.81%)

7/8/2008 4:00 PM

Ligand Pharmaceuticals, Inc. (LGND)

CAPS Rating:

Develops and markets new drugs that address critical unmet medical needs in the areas of cancer, mens and womens health, skin diseases, osteoporosis, and metabolic, cardiovascular and inflammatory diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating LGND

Add Stock to Watchlist

What the Community Thinks

Total Players

73 Outperforms

15 Underperforms

All-Stars

10 Outperforms

7 Underperforms

Wall Street

3 Outperforms

1 Underperforms

Players bullish on LGND are also bullish on:

Players bearish on LGND are also bearish on:

Ticker Tags

Micro Cap (4824), Drug Manufacturers - Other (105)
Suggest a tag

Ligand Pharmaceuticals, Inc. At A Glance

Current Price:	$2.91
Last Trade Time:	7/8/2008 4:00 PM
Open:	$2.66
Previous Close:	$2.65
Daily Range:	$2.66 - $2.96
52-Week Range:	$2.16 - $7.36
Volume:	451,193
Market Cap:	$251.53M
P/E Ratio:	0.00
Compare Our Special Broker Offers!

Stock Trends

LGND VS S&P 500 (SPY)

News & Discussion Boards

Other News Headlines for LGND

Ligand says FDA extends blood-clot drug review
6/20/2008 4:31:00 PM - AP
Alphatec Spine names Peter Wulff as CFO
6/16/2008 9:00:00 AM - AP

More Headlines...

Top Bull Pitch

Recs

2 Ligand Pharmaceuticals, Inc. (LGND)

Avatar humvee5000 (98.02) Submitted: 4/19/07 1:24 PM

I really screwed up on this one. Bought it quickly and added it to Caps without really doing DD. Got the divi
but lost the war. I did a really amateurish move. Thinking that the stock price would not go down the 2.50 that they were giving out in the divi. As I researched -- seems near term th...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

Show Me:

Sort by:

picks per page. CHANGE

Results 1 - 5 of 13 : 1 2 3 Next »

Recs 0 (LGND) zzlangerhans (78.80) Submitted: 6/25/08 9:49 PM : Start Price: $2.49 LGND Score: 19.81 The Ligand situation has become extremely complex. After a steady erosion in the stock price over the last year, the short-term story is now the FDA action on the thrombopoietin mimetic Promacta. The FDA initially posted a position paper on their website suggesting that Promacta was no more effective than placebo in reducing bleeding in ITP, and the stock tanked. Then the advisory panel turned around and recommended approval unaminously, and the stock shot back up to prior levels. The price has now drifted back down, helped along by the FDA decision to delay the PDUFA data by three months into September. It's virtually impossible to analyze the data and decide whether the FDA or the advisory panel got the numbers right. The only real question is whether the FDA will go against the unaminous vote and basically prove that it only follows advisory panel recs that it already agrees with, or whether they will submit to the recommendation. It's a toss-up, and the only reason for the outperform rating is that the market cap has dropped almost down to the level it was at after the FDA position paper was released, basically pricing in an approvable letter. I expect at least a 15% rise at some point in the months between now and the actual decision. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (LGND) jurkovich (39.23) Submitted: 5/28/08 2:18 PM : Start Price: $2.27 LGND Score: -36.39 They just had their top drug flushed by the FDA advisory committee. They have nothing going for them. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (LGND) kurthauer1998 (95.93) Submitted: 5/19/08 2:22 PM : Start Price: $3.67 LGND Score: 9.60 Appears to have no direction and bad ratios. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (LGND) Caedus (41.66) Submitted: 3/13/08 11:34 PM : Start Price: $4.01 LGND Score: -23.24 As patents for drugs begin to expire this year, many Japanese drug companies are looking to smaller U.S. based corporations to get a foothold on new products to offset their anticipated losses from the expiration of the patents. I foresee LGND being considered for acquisition, and the speculation will likely drive it's price up. They also have several upcoming releases which will spark their sales % upwards pending FDA approvals, and their current price is far below it's future potential. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out. Recs 0 (LGND) ImmortalThanos (73.47) Submitted: 2/28/08 11:26 AM : Start Price: $3.67 LGND Score: 13.61 Avoid this like the plague. This is another one of those "Jack Of All Trades" companies that never really gets anywhere. Skip this until they get a better mission statement developed. Report this Post Replies: 0 \| Reply \| Permalink Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Results 1 - 5 of 13 : 1 2 3 Next »

Wall Street

Results 1 - 4 of 4

picks per page. CHANGE

Top Pick	Player Name	Player Rating	Start Date	Call	Time Frame	Start Price	Stock Gain	S&P Gain	Score	Pitch
	TrackBroadpointC	76.55	06/23/08		NS	$2.73	+6.59%	-3.70%	+10.30
	TrackSusquehanna	< 20	12/07/07		NS	$4.81	-39.50%	-16.00%	-23.51
	TrackJimCramer	83.15	01/08/07		3W	$8.53	-65.89%	-9.89%	+56.00
	TrackFirstAlbany	76.93	09/11/06		NS	$7.98	-63.53%	-2.05%	-61.48

Results 1 - 4 of 4

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.